Lineage Cell Therapeutics, Inc. (TLV: LCTX)

Market Cap	637.11M
Revenue (ttm)	23.29M
Net Income (ttm)	-91.07M
Shares Out	n/a
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,187
Open	325.30
Previous Close	325.30
Day's Range	325.30 - 343.00
52-Week Range	3.03 - 343.00
Beta	1.26
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 75
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: LCTX

Financial Performance

In 2023, Lineage Cell Therapeutics's revenue was $8.95 million, a decrease of -39.16% compared to the previous year's $14.70 million. Losses were -$21.49 million, -18.22% less than in 2022.

Financial numbers in USD